Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM0WTMD)

• Drug Name: DSP-2230 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Neuropathic pain	8E43.0	Phase 1	[1]

• Cross-matching ID:
  PubChem CID: 129080919
  TTD Drug ID: DM0WTMD
  VARIDT Drug ID: DR01053

Molecule-Related Drug Atlas

Drug(s) Targeting Voltage-gated sodium channel alpha Nav1.7 (SCN9A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
XEN-402	DMR69CG	Osteoarthritis	FA00-FA05	Phase 2	[2]
PF-05089771	DMD74BJ	Chronic pain	MG30	Phase 2	[3]
BIIB074	DMLV1ET	Bipolar disorder	6A60	Phase 2	[1]
BIIB095	DMUC6EP	Pain	MG30-MG3Z	Phase 1	[1]
GDC0310	DMUNFEP	Chronic pain	MG30	Phase 1	[4]
DSP-3905	DMYHU24	Neuropathic pain	8E43.0	Phase 1	[1]
PF-05241328	DM2NTBL	Pain	MG30-MG3Z	Phase 1	[5]
DWJ-208	DMQKDJZ	Cancer related pain	MG30	Phase 1	[1]
RG7893	DM1R4MQ	Pain	MG30-MG3Z	Phase 1	[6]
PF-05186462	DMUF6W9	Pain	MG30-MG3Z	Phase 1	[7]

Drug(s) Targeting Voltage-gated sodium channel alpha Nav1.8 (SCN10A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Rilpivirine	DMJ0QOW	Human immunodeficiency virus infection	1C62	Approved	[8]
Ropivacaine	DMSPJG2	Anaesthesia	9A78.6	Approved	[9]
Bupivacaine	DM4PRFC	Anaesthesia	9A78.6	Approved	[9]
Tiapride	DMN6CAG	Alcohol dependence	6C40.2	Approved	[10]
Tetracaine	DM9J6C2	Spinal anesthesia	MB40.3	Approved	[11]
Proparacaine	DMLS39E	Anaesthesia	9A78.6	Approved	[9]
Conatumumab	DM2UOSN	Colorectal cancer	2B91.Z	Phase 2	[12]
VX-150	DMGDB21	Neuropathic pain	8E43.0	Phase 2	[4]
PF-01247324	DM93LMS	Pain	MG30-MG3Z	Phase 1	[13]
VX-128	DMC8J0G	Pain	MG30-MG3Z	Phase 1	[4]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Voltage-gated sodium channel alpha Nav1.7 (SCN9A)	TT4G2JS	SCN9A_HUMAN	Inhibitor	[1]
Voltage-gated sodium channel alpha Nav1.8 (SCN10A)	TT90XZ8	SCNAA_HUMAN	Inhibitor	[1]

References

• [1] Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357.
• [2] Treatment of Na(v)1.7-mediated pain in inherited erythromelalgia using a novel sodium channel blocker. Pain. 2012 Jan;153(1):80-5.
• [3] Primary erythromelalgia: a review. Orphanet J Rare Dis. 2015 Sep 30;10:127.
• [4] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [5] Recent progress in sodium channel modulators for pain. Bioorg Med Chem Lett. 2014 Aug 15;24(16):3690-9.
• [6] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800041740)
• [7] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800026875)
• [8] Structures of muO-conotoxins from Conus marmoreus. I nhibitors of tetrodotoxin (TTX)-sensitive and TTX-resistant sodium channels in mammalian senso... J Biol Chem. 2004 Jun 11;279(24):25774-82.
• [9] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [10] Emerging drugs in neuropathic pain. Expert Opin Emerg Drugs. 2007 Mar;12(1):113-26.
• [11] Heterologous expression and functional analysis of rat Nav1.8 (SNS) voltage-gated sodium channels in the dorsal root ganglion neuroblastoma cell line ND7-23. Neuropharmacology. 2004 Mar;46(3):425-38.
• [12] Pathobiology of visceral pain: molecular mechanisms and therapeutic implications. II. Genetic approaches to pain therapy. Am J Physiol Gastrointest Liver Physiol. 2000 Apr;278(4):G507-12.
• [13] Oral Administration of PF-01247324, a Subtype-Selective Nav1.8 Blocker, Reverses Cerebellar Deficits in a Mouse Model of Multiple Sclerosis. PLoS One. 2015; 10(3): e0119067.